



Cumulative Index 2002

Volume 29

March	RECENT ADVANCES IN NEONATAL GASTROENTEROLOGY, pages 1–201
June	NEONATAL NUTRITION, pages 203–356
September	PAIN IN VULNERABLE INFANTS, pages 357–583
December	PERINATAL BRAIN INJURY, pages 585–882

Note: Page numbers of article titles are in **bold** face type.

**A**

Abdominal wall, gastroschisis of, surgical treatment of, 11–12

Acetaminophen  
maternal, neonatal effects of, 514  
metabolism of, polymorphisms in, 524–525  
pharmacokinetics of, 520–521

Acetoacetate, as cerebral metabolism fuel, 654–655

Acidosis, bilirubin neurotoxicity in, 766, 770

Activity, in pain assessment, 482

Acyclovir, for herpes simplex virus infections, 807–809

Adrenergic nerve stimulation, intestinal circulation response to, 31

Adrenocorticotropin, as pain marker, 420–421

Aganglionosis (Hirschsprung's disease)  
pathophysiology of, 98  
surgical treatment of, 10–11

Aggressive nutrition, for preterm infants  
description of, 227  
enteral, 237–241  
parenteral, 230–237

Agitation, versus pain, 479

Airway obstruction, ex utero intrapartum therapy for, 4

Alagille syndrome, cholestasis in, 168–169

Albumin, in bilirubin binding, 765, 767, 770

Aldosterone, as pain marker, 421

Alfentanil  
adverse effects of, 502  
for premedication, for endotracheal intubation, 543, 549  
pharmacodynamics of, 498  
pharmacokinetics of, 496

Allopurinol, for hypoxic-ischemic brain injury, 682–683

Amino acids  
in parenteral nutrition, for very low birthweight infants, 231–233  
metabolic defects of, hypoglycemia in, 253  
placental transfer of, 208–213  
requirements for, in infections, 297–299

Amphtericin B, for fungal infections, 813–814

Ampicillin, for bacterial meningitis, 797

Anaerobic bacteria, in meningitis, 802

Analgesia. *See also Opioids: specific agents.*  
changing attitudes toward, 557–558  
effects of, 511–534  
developmental considerations  
in utero, 512–516  
long-term, 525–526  
maternal, 513–514  
metabolism and, 514–516  
opioids, 516–517  
pharmacokinetics and, 517–522  
polymorphisms and, 522–525

receptor variability and, 525–526  
tolerance, 518

Anemia of prematurity, 283–294  
causes of, 284  
erythropoietin in  
    deficiency of, 283–284  
    replacement of, 287–289  
evaluation of, 285–286  
    in nutritional assessment, 323  
iron in  
    metabolism of, 285  
    requirements for, 284–285  
    supplementation of, 288–289  
long-term studies of, 289–290  
transfusions for, 286–287

Anesthesia  
    changing attitudes toward, 557–558  
    failure to use, 559–562  
    for fetus, 366–367  
    in stress response suppression, 417–419  
standards of care for, 567

Angiotensin II, constrictor activity of, in necrotizing enterocolitis, 34

Anomalies, gastrointestinal. *See* Gastroenterology, anomalies.

Anorectoplasty, posterior sagittal, for imperforate anus, 14

Anoxia, brain injury in. *See* Hypoxic-ischemic brain injury.

Antacids, for gastroesophageal reflux, 152

Anthropometric measurements, for nutritional assessment, in preterm infants, 318

Antibiotics, for chorioamnionitis, 615

Antibodies, in breast milk, 42–43

Anticoagulant therapy, for stroke, 715

Anticonvulsants, for hypoxic-ischemic brain injury, 679–680

Antiphospholipid antibody syndrome, maternal, fetal and newborn stroke in, 695

$\alpha_1$ -Antitrypsin deficiency, cholestasis in, 173

Anus, imperforate, surgical treatment of, 13–14

Apnea  
    in gastroesophageal reflux, 140, 145  
    in very low birthweight infants, brain injury in, 781

Apoptosis, in hypoxic-ischemic brain injury, 594–595

Arachidonic acid  
    in nutrition

adverse effects of, 274–275  
cognitive-behavioral development and, 270–273  
deficiency of, 267  
formation of, 267  
in breast milk, 266  
in formulas, 266, 269, 276  
structure of, 264  
visual function and, 269–270  
mediators of, 592–593

Arginine, in nutrition, 56, 73

Arterial pressure, reduction of, intestinal circulation response to, 30

asc amino acid transporters, 208–209

Aspartate, in hypoglycemia, 657

Asphyxia  
    brain injury in. *See* Hypoxic-ischemic brain injury.  
    diving reflex in, 32–33

ATA1 amino acid transporter, 209

ATB amino acid transporters, 208

Atracurium, for premedication, for endotracheal intubation, 539–540, 544

Atresia, esophageal, surgical treatment of, 8–9

Atropine, for premedication, for endotracheal intubation, 539–542, 544–547, 549

Autoimmune diseases, maternal, fetal and newborn stroke in, 695

Autonomic nervous system, in heart rate control, 430–431

Autoregulation, pressure-flow, in intestinal circulation, 30

Autoregulatory escape, in intestinal circulation response, 31

---

**B**

Bacterial overgrowth, in short-bowel syndrome, 187–188

*Bacteroides fragilis*, in meningitis, 802

Barbiturates, for hypoxic-ischemic brain injury, 681–682

Barker thrifty phenotype hypothesis, 203–205, 328–329

Basal ganglia injury, in very low birthweight infants, 778–779

Beckwith-Wiedemann syndrome, hypoglycemia in, 248

Behavioral outcome  
 in very low birthweight infants. *See*  
 Very low birthweight infants, brain  
 injury in.  
 of pain, in ex-preterm children, 357–359,  
 378–379  
 of stroke, 715

Behavioral state, in pain assessment, 471–473

Benzathine penicillin G, for syphilis, 800–801

Beta cells, partial excision of, for  
 hyperinsulinemia, 15

Beta-hydroxybutyrate, as cerebral metabolism  
 fuel, 654–655

Bethanechol  
 for gastroesophageal reflux, 151  
 pharmacology of, 119–120

Bianchi procedure, for short-bowel  
 syndrome, 189

Bicarbonate, as pain marker, 676

Bifidobacteria, as immunonutrients, 58

Biliary tract  
 atresia of, cholestasis in, 163, 165–166  
 bile formation in, physiology of, 161–162  
 cholestatic disease of. *See Cholestasis.*  
 dysgenesis of, cholestasis in, 167–168  
 paucity of ducts in, cholestasis in, 168  
 secretions from, in host defense, 43–44

Bilirubin  
 excess of, in cholestasis. *See Cholestasis.*  
 measurement of, in nutritional  
 assessment, of preterm infants, 322  
 neurotoxicity of, 763–776  
 blood–brain barrier and, 765  
 blood flow and, 766  
 chemistry in, 764  
 clinical implications of, 768–769  
 drug effects on, 767  
 factors increasing, 766–767  
 hyperbilirubinemia interventions in,  
 767–768  
 immaturity issues in, 771–772  
 in hemolysis, 771  
 in very low birthweight infants,  
 782–783  
 mechanism of, 768  
 metabolism and, 766  
 treatment of, 769–771

Biological markers, of pain, 415–425  
 aldosterone, 421  
 catecholamines, 419–420  
 cortisol, 420–421  
 endorphins, 421  
 glucagon, 421

growth hormone, 422  
 in anesthesia, 417–418  
 in surgery, 417–418

insulin, 421

prolactin, 422

renin, 421

stress response and, 416–419

Biopsy, liver, in biliary atresia, 166

Birth trauma, stroke in, 705

Birthweight  
 adult and childhood nutritional  
 abnormalities related to, 203–205,  
 213–214  
 regaining of, in premature infants, 318  
 very low. *See Extremely low*  
 birthweight infants; Very low  
 birthweight infants.

Blood–brain barrier, bilirubin entry through,  
 765–767, 770

Blood flow, cerebral  
 autoregulation of, in vulnerable neonates,  
 380  
 bilirubin entry and, 766  
 periventricular leukomalacia and, 751

Blood pressure  
 breastfeeding effects on, 215  
 in endotracheal intubation, premedication  
 effects on, 538–542, 544–549  
 in postoperative pain assessment, 474  
 reduction of, intestinal circulation  
 response to, 30

Blood urea nitrogen, in nutritional assessment,  
 of preterm infants, 323

Body language, in pain assessment, 450,  
 471–473, 475, 483

Bombesin, trophic effects of, 78

Bone metabolism, corticosteroids effects on,  
 304–305

Borreliosis, of central nervous system,  
 805–806

Bradycardia  
 in very low birthweight infants, brain  
 injury in, 781  
 opioid-induced, 502

Brain  
 development of, pain effects on.  
*See Neurodevelopmental effects,*  
 of pain.  
 edema of, in hypoxic-ischemic brain  
 injury, 679  
 glucose transporters in, 655

metabolism of, hypoglycemia and, 655-656

**Brain injury**  
hemorrhagic-ischemic, in preterm infants, 743-761  
hypoglycemic, 649-672  
hypoxic-ischemic. *See Hypoxic-ischemic brain injury.*  
in bilirubin toxicity, 763-776  
in chorioamnionitis, 603-621, 753  
in infections, 797-824  
in periventricular-intraventricular hemorrhage, 743-750  
in periventricular leukomalacia, 750-755  
in stroke, 691-722  
in very low birthweight infants, 777-795

Branched-chain  $\alpha$ -keto acid dehydrogenase deficiency, hypoglycemia in, 253

**Breast milk**  
bile salts in, 263  
components of, in gastrointestinal host defense, 42-43  
fatty acids in, 266  
feedings with, for very low birthweight infants, 239-240, 783  
for gastroesophageal reflux, 150  
fortified, for preterm infants, 314-317  
lipids in, 261

**Breastfeeding**  
adult nutritional disorders and, 215-216  
of preterm infants, 338

Bronchopulmonary dysplasia  
corticosteroids for, 303  
nutrition in, 339-340

Bupivacaine  
maternal, neonatal effects of, 514  
pharmacokinetics of, 521-522

Butyric acid, in nutrition, 58-59, 75-76

Byler disease (progressive familial intrahepatic cholestasis), 171-172

**C**

**Calcium**  
accumulation of, in hypoxic-ischemic brain injury, 589  
in formulas, for preterm infants, 337  
levels of, in hypoglycemia, 657

Calcium channel blockers  
for hypoxic-ischemic brain injury, 681  
for persistent hyperinsulinemic hypoglycemia of infancy, 250

Calorimetry, indirect, for energy expenditure measurement, 299

*Candida*, in central nervous system infections, 813-814

Candidemia, catheter-related, in short-bowel syndrome, 188

Carbohydrate(s). *See also Glucose.*  
malabsorption of, in short-bowel syndrome, 184  
metabolic disorders of, hypoglycemia in, 251-253  
supplements for, for preterm infants, 316-317

Cardiopulmonary resuscitation, stroke in, 706

Cardiovascular disease, in adults, early nutrition impact on, 203-204

Cardiovascular effects, of opioids, 502

Carnitine deficiency  
hypoglycemia in, 253-254  
in infections, 300

Caroli's disease, cholestasis in, 167

CAT amino acid transporters, 208

Catabolism, in infections, nutritional aspects of, 296-302

Catalase deficiency, in hypoxic-ischemic brain injury, 590

Catecholamines, as pain marker, 419-420

Catheters  
central venous, for gastrointestinal disorders, 10  
sepsis associated with, in short-bowel syndrome, 188

Cefotaxime  
for bacterial meningitis, 798  
for Lyme disease, 806

Ceftriaxone, for Lyme disease, 806

Central nervous system. *See also Brain.*  
enteric nervous system interactions with, 98

Central venous catheters, for gastrointestinal disorders, 10

Cerebral arteries, immature, periventricular leukomalacia and, 751

Cerebral blood flow  
autoregulation of, in vulnerable neonates, 380  
bilirubin entry and, 766  
hypoglycemia and, 655-656  
periventricular leukomalacia and, 751

Cerebral palsy  
chorioamnionitis and

clinical features of, 605–606  
genetic factors in, 613  
in encephalopathy, 608–612  
in premature infants, 606–608  
in term infants, 606  
prevention of, 614–615  
susceptibility to, 612–613

due to maternal therapy. *See Neurodevelopmental effects of maternal therapies.*

postoperative pain assessment in, 480–485

Cerebral venous thrombosis, stroke in, 707

Checklist Pain Behavior, 484

Chemokines  
in hypoxic-ischemic brain injury, 592  
intestinal, in host defense, 49–51

Chickenpox, central nervous system involvement in, 812

Child Facial Coding System, for pain assessment, 478

Children's and Infants' Postoperative Pain Scale, 472, 476

Children's Hospital of Eastern Ontario Pain Scale (CHEOPS), 471, 473, 475–476

Cholangiography, in biliary atresia, 166

Cholangitis, sclerosing, 167

Cholecystokinin, trophic effects of, 77–78

Cholestasis, neonatal, 159–180  
approach to, 162–163  
causes of  
    bile flow impairment, 161–162  
    extrahepatic bile duct lesions, 163–167  
    genetic defects, 170–174  
    hepatobiliary transporter defects in, 171–172  
    hepatocyte disorders, 169–171  
    in parenteral nutrition, 174, 187  
    intrahepatic bile duct lesions, 167–169  
    metabolic liver diseases, 172–174  
clinical features of, 160–161  
evaluation of, 160–161  
laboratory studies in, 160–161  
physiologic, 162  
susceptibility to, 162  
treatment of, 174–175

Cholesterol levels, breastfeeding effects on, 215

Cholestyramine, for short-bowel syndrome, 186

Cholylsarcosine, for short-bowel syndrome, 189

Chorioamnionitis, 603–621  
antibiotics for, neurodevelopmental effects of, 726–731  
brain injury in  
    cerebral palsy and. *See Cerebral palsy, chorioamnionitis and.*  
    clinical features of, 605–606  
    developmental delay in, 608  
    encephalopathy, 608–612  
    periventricular leukomalacia, 753  
    prevention of, 614–615  
    susceptibility to, 612–613  
definition of, 604  
incidence of, 604  
microbiologic evidence of, 605  
organisms causing, 603–604

Chorioretinitis  
in cytomegalovirus infections, 809–810  
in toxoplasmosis, 815–817

Chronic lung disease, in very low birthweight infants, brain injury in, 781

Cimetidine, pharmacology of, 124–126

Circulation, intestinal. *See Intestinal circulation.*

Circumcision  
anesthesia for, stress response in, 417  
pain perception in, heart rate in, 433–434

Cisapride  
for gastroesophageal reflux, 151–152  
pharmacology of, 120–122

Citric acid cycle, glutamine in, 52

*Citrobacter diversus*, in meningitis, 799

Clinical Scoring System, for pain assessment, 471, 473–474, 476

*Clostridium*, in meningitis, 802

Coagulation disorders, maternal, fetal and newborn stroke in, 695–698

Cocaine exposure, intrauterine, fetal and newborn stroke in, 698–699

Cognitive-behavioral development, dietary fatty acids and, 270–273

Cognitive dysfunction  
chorioamnionitis related to, 606  
in ex-preterm children, 357–359, 378–379  
in stroke, 714–715  
in very low birthweight infants.  
*See Very low birthweight infants, brain injury in.*

postoperative pain assessment in, 480–485

Colon  
Hirschsprung's disease of, 10–11, 98  
malrotation of, surgical treatment of, 9

Colostomy, for imperforate anus, 14

Colostrum, for very low birthweight infants, 240

COMFORT, for pain assessment, 462, 472, 474, 476

Communication, of pain, 446–454, 553, 555–556

Conceptual age, versus pain response, heart rate variability and, 434–436

Congenital anomalies  
cardiac, growth failure in, 340  
gastrointestinal. *See*  
Gastroenterology, anomalies.

Consciousness, in fetus, 366–367

Consolability, in pain assessment, 471–474

Constipation, opioid-induced, 502–503

Corticosteroids  
gastrointestinal trophic effects of, 84  
indications for, 302–303  
maternal, neurodevelopmental effects of, 733–735  
metabolic effects of, 302–307  
energy expenditure, 306  
implications of, for feeding, 307  
in bronchopulmonary dysplasia, 303  
in growth and development, 303–305  
lipids, 307  
protein, 305–306  
periventricular-intraventricular hemorrhage and, 748

Cortisol  
as pain marker, 420–421  
in fetus, 512  
deficiency of, hypoglycemia in, 250–251

Cortisone, for hypoglycemia, in infants of diabetic mothers, 248

Coxsackievirus, in central nervous system infections, 809–810

CRIB acronym, for pain assessment, 461–462, 471–472, 476, 480

Crigler-Najjar syndrome, morphine metabolism in, 518

Critical illness, pain assessment in, 479–480

Crying, in pain assessment, 449, 471–473, 475, 482

Cyclomydril, gastrointestinal effects of, 127–128

Cyclooxygenase, in hypoxic-ischemic brain injury, 592–593

Cystic adenomatoid malformation, fetal surgery for, 4

Cystic fibrosis, cholestasis in, 173

Cytokines  
gastrointestinal trophic effects of, 84–85  
in brain injury, associated with chorioamnionitis, 614  
in hypoxic-ischemic brain injury, 591–592, 594  
in periventricular leukomalacia, 753  
intestinal, in host defense, 49–51

Cytomegalovirus, in central nervous system infections, 809–810

---

**D**

Dehydration, in hyperglycemia, 255

Dendritic cells, intestinal, in host defense, 48

Denial, of neonatal pain, management decisions and, 563–565

Desensitization, in neonatal care workers, pain management decisions and, 563–565

Dexamethasone  
for bacterial meningitis, 799  
gastrointestinal effects of, 84, 128  
metabolic effects of, 303  
energy expenditure, 306  
in growth and development, 304  
lipids, 307  
protein, 305

Diabetes mellitus  
maternal  
infants of, hypoglycemia in, 247–248  
suboptimal intrauterine growth and, 204–205  
type 2, breastfeeding protection against, 216

Diaphragmatic hernia, prenatal versus postnatal, 3–4

Diazoxide, for persistent hyperinsulinemic hypoglycemia of infancy, 250

Diclofenac, maternal, neonatal effects of, 514

Diet. *See* Nutrition.

Diving reflex, necrotizing enterocolitis pathophysiology and, 32–33

Docosahexaenoic acid, in nutrition adverse effects of, 274–275 cognitive-behavioral development and, 270–273 deficiency of, 267 formation of, 267 in breast milk, 266–268 in formulas, 267, 269, 276 sources of, 273 structure of, 264 visual function and, 268–270

Doxapram, brain injury due to, 781

Drainage, peritoneal, for necrotizing enterocolitis, 12–13

Drugs, gastrointestinal effects of. *See* Pharmacology, of gastrointestinal tract.

**E**

EAAT amino acid transporters, 209

Échelle Douleur Inconfort Nouveau-Né, for pain assessment, 471–472, 476

Echogenic bowel, in fetus, 3

Echovirus, in central nervous system infections, 809–810

Ectoderm, enteric nervous system derived from, 99

Edema, cerebral, in hypoxic-ischemic brain injury, 679

Eicosapentaenoic acid, structure of, 264

Electroencephalography, in stroke, 708–709

Embryology, of enteric nervous system, 99–102

Encephalitis  
herpes simplex virus, 806–809 stroke in, 705

Encephalopathy  
HIV, 811  
hypoxic. *See* Hypoxic-ischemic brain injury.  
in chorioamnionitis, 608–612

Endoderm, enteric nervous system derived from, 99

Endorphins, endogenous, as pain markers, 421

Endoscopy, in gastroesophageal reflux, 149

Endosomes, intestinal, in host defense, 47

Endothelins  
in enteric nervous system development, 106–107  
in intestinal circulation regulation, 28–29  
in necrotizing enterocolitis, 34–35

Endothelium, dysfunction of, in necrotizing enterocolitis, 33–36

Endotracheal intubation, premedication for, 535–552

Energy  
expenditure of, corticosteroids effects on, 306  
failure of, in hypoxic-ischemic brain injury, 587, 632–634  
requirements of  
for fetal growth, 228–230  
for very low birthweight infants, 240–241  
in infections, 299–301

Enteral feeding  
for short-bowel syndrome, 183–184  
for very low birthweight infants, 237–241  
minimal, intestinal mucosal effects of, 67–68

Enteric nervous system, 97–114  
components of, 98  
development of  
embryologic, 99–102  
molecular biology of, 105–109  
molecular marker studies of, 103–104  
mutant animal studies of, 103  
signaling pathways in, 105–108  
tissue recombination studies of, 102–103  
transcriptional regulation of, 108–109  
transgene markers for, 104–105  
disorders of, 98  
immaturity of, 99  
physiology of, 97–98

Enterobacteriaceae, in meningitis, 798

Enterocolitis, necrotizing. *See* Necrotizing enterocolitis.

Enterocytes, apical membrane of, in host defense, 47

Enteroviruses, in central nervous system infections, 809–810

Environmental factors  
in brain injury, in very low birthweight infants, 784–787

in neurodevelopment, 382–388  
postdischarge, for very low birthweight infants, 787

Enzymes, in intestinal cells, in host defense, 47

Epidermal growth factor, gastrointestinal trophic effects of, 79–81

Epinephrine  
as pain marker, 419–420  
for hypoxic-ischemic brain injury, 675–676

Epithelium and epithelial cells  
intestinal, in host defense, 45–47, 50–51  
signaling by, in enteric nervous system development, 108

Erythroblastosis fetalis, hypoglycemia in, 248

Erythromycin  
for gastroesophageal reflux, 152  
pharmacology of, 122–124

Erythropoietin  
deficiency of, in anemia of prematurity, 283–284  
replacement of, in anemia of prematurity, 287–289

Esophagitis, ir, gastroesophageal reflux, 144–145

Esophagus  
atresia of, surgical treatment of, 8–9  
gastric contents reflux into. *See* Gastroesophageal reflux.

Ethical issues, in pain management, 566–567

Etomidate, surgical stress response suppression due to, 418

Ex utero intrapartum therapy, for airway obstruction, 4

Excitotoxicity  
in hypoxic-ischemic brain injury, 588–589, 635–636  
in periventricular leukomalacia, 752

EXIT (ex utero intrapartum therapy), for airway obstruction, 4

Extracorporeal membrane oxygenation, stroke in, 706

Extremely low birthweight infants  
definition of, 329  
long-term growth of, 332  
pain sensitivity and assessment in, 479–480

Eye infections, cytomegalovirus, 809–810

**F**

FABP lipid transporter, 208

Face, Legs, Activity, Cry, and Consolability, for pain assessment, 473, 476

Facial expression, in pain assessment, 449–450, 471–473, 482

Famotidine, pharmacology of, 124–126

FAT lipid transporter, 208

FATP lipid transporter, 208

Fatty acids  
essential, 264–268. *See also* Long-chain polyunsaturated fatty acids.  
for very low birthweight infants, 783

for bilirubin neurotoxicity, 769

for hyperglycemia, 255–256

in parenteral nutrition, for very low birthweight infants, 234–236

long-chain, 56–57, 76–77

metabolic defects of, hypoglycemia in, 253–254

short-chain, 75–76

Feeding. *See also* Formulas; Nutrition.  
intestinal circulation response to, 31  
tolerance of, in preterm infants, 316, 318

Fentanyl  
adverse effects of, 502  
clinical efficacy of, 500  
for fetal surgery, 367  
for premedication, for endotracheal intubation, 536, 540–541, 544, 549  
metabolism of, polymorphisms in, 524  
pharmacodynamics of, 498  
pharmacokinetics of, 495–496, 519–520  
surgical stress response suppression due to, 417–418  
tolerance of, 503, 518

Fetus  
consciousness of, 366–367  
gastrointestinal anomalies in, 2–5  
intestinal circulation of, basal vascular resistance in, 24–25  
nutrition in  
before implantation, 205  
for cardiovascular health, 203–204  
for growth, 204–205  
placental transfer of, 205–208  
    amino acids, 208–213  
    glucose, 207–210  
    in pathologic states, 213–215  
    lipids, 208, 212–213

pain in  
analgesia for, 512–516

anesthesia for, 366-367  
brain development and, 361-362,  
366-367  
perception of, 366-367, 512-516  
stress response in, 383

Fever  
in hypoxic-ischemic brain injury, 642  
maternal, neonatal encephalopathy and,  
609-612

Fibrinolysis, periventricular-intraventricular hemorrhage in, 744-745

Fibroblast growth factor, gastrointestinal trophic effects of, 82

*FIC1* gene mutations, in progressive familial intrahepatic cholestasis, 171-172

Fish oils, long-chain polyunsaturated fatty acids in, 273-274

Fluconazole, for fungal infections, 814

Fluid and electrolyte balance, in nutritional assessment of preterm infants, 322

Fluid therapy  
for hypoxic-ischemic brain injury,  
676-678  
for short-bowel syndrome, 183

5-Fluorocytosine, for fungal infections,  
813-814

Fluoroscopy, in gastroesophageal reflux, 148

Fontanelle, pressure in, in endotracheal intubation, premedication effects on, 539,  
544, 547

Formulas  
for cholestasis, 175  
for preterm infants, 314-317  
fatty acids in, 266-270, 276  
post-discharge, 334-336  
macronutrient composition of, 70-71  
versus breast milk  
gastroesophageal reflux and, 150  
nutritional aspects of, 68-70

Foscarnet, for cytomegalovirus infections,  
809-810

Free radicals  
in hypoxic-ischemic brain injury,  
589-590, 594, 637-638  
in periventricular leukomalacia, 752

Fructose 1,6-diphosphatase deficiency,  
hypoglycemia in, 251-252

Fructose 1,6-diphosphate aldolase deficiency,  
hypoglycemia in, 252-253

Fructose intolerance, hypoglycemia in,  
252-253

Fuller Infant Pain Assessment Tool, clinical utility of, 462-463

Fundoplication, for gastroesophageal reflux,  
7-8, 153

Fungal infections, of central nervous system,  
813-815

Funisitis, periventricular leukomalacia and,  
753-754

**G**

Galactose-1-phosphate uridyl transferase deficiency, hypoglycemia in, 252

Ganciclovir, for cytomegalovirus infections,  
809-810

Ganglion cells  
absence of, in Hirschsprung's disease,  
10-11, 98  
in enteric nervous system, 98, 101-102

Gastric acid, in host defense, 43-44

Gastrin, trophic effects of, 77-78

Gastrin-releasing peptide, trophic effects of, 78

Gastroenterology. *See also* Nutrition.  
anomalies, 1-21  
esophageal atresia, 8-9  
fetal surgery for, 2-5  
gastroesophageal reflux in, 7-8  
gastroschisis, 11-12  
Hirschsprung's disease, 10-11, 98  
hyperinsulinism, 14-15  
imperforate anus, 13-14  
inguinal hernia, 8  
malrotation, 9-10  
minimally invasive surgery for,  
5-10  
necrotizing enterocolitis in, 12-13  
prenatal diagnosis of, 2-5  
pyloric stenosis, 6-7  
transplantation in, 15-16  
cholestasis, 159-180  
cytokines, 84-85  
enteric nervous system, 97-114  
gastroesophageal reflux. *See*  
Gastroesophageal reflux.  
glucocorticoids, 83-84  
growth factors, 79-85  
hormones, 77-84  
host defense, 41-51  
intestinal circulation, 23-39

key nutrients in, 65–96  
peptide growth factors, 79–84  
pharmacology, 115–133  
short gut, 181–194

Gastroesophageal reflux, 135–158  
  clinical patterns of, 143–145  
  defense mechanisms for, 140–143  
  definition of, 135  
  diagnosis of, 146–149  
  differential diagnosis of, 145–146  
  embryologic physiology and, 137–138  
  incidence of, 136  
  pathophysiology and pathogenesis of, 136–143  
  physiologic, versus pathologic, 146  
  prevalence of, 136  
  refluxate composition in, 140  
  risk factors for, 136–137  
  surgical treatment of, 7–8  
  treatment of, 149–153

Gastroschisis, surgical treatment of, 11–12

Gastrostomy, for gastroesophageal reflux, 7–8, 153

Genetic factors  
  in brain injury, associated with  
    chorioamnionitis, 613  
  in neonatal cholestasis, 170–174

Gentamicin, for bacterial meningitis, 797–799

GER. *See* Gastroesophageal reflux.

Germline matrix intraventricular hemorrhage.  
*See also* Periventricular-intraventricular hemorrhage.  
  neuroimaging in, 831–832

Gestational age, versus pain response, heart rate variability and, 434–436

Gilbert's syndrome, morphine metabolism in, 518

GLAST amino acid transporter, 209

Glial cell line-derived neurotrophic factor, in enteric nervous system development, 107–108

GLT amino acid transporter, 209

Glucagon  
  as pain marker, 421  
  for persistent hyperinsulinemic hypoglycemia of infancy, 250

Glucagon-like peptide 2  
  for short-bowel syndrome, 188–189  
  trophic effects of, 78–79

Glucocorticoids. *See* Corticosteroids.

Glucokinase defects, in persistent hyperinsulinemic hypoglycemia of infancy, 249–250

Glucose  
  extremes of. *See* Hypoglycemia;  
    Hypoglycemia.  
  homeostasis of, 245–246  
  metabolism of, 652–654  
  monitoring of, in nutritional assessment,  
    of preterm infants, 322  
  parenteral  
    for hypoglycemia, 667–668  
      in infants of diabetic  
        mothers, 248  
      in small-for-gestational-age  
        infants, 249  
    for hypoxic-ischemic brain  
      injury, 679  
    for infections, 301  
    for very low birthweight infants,  
      233–234  
  placental transfer of, 207–210, 214  
  supplements for, for preterm infants,  
      316–317  
  utilization of, hypoglycemia and,  
      655–656

Glucose-6-phosphatase deficiency,  
  hypoglycemia in, 251

Glucose intolerance  
  in very low birthweight infants, 233–236  
  suboptimal intrauterine growth and,  
      204–205

Glucose transporters, 207–210, 655

Glutamate  
  accumulation of  
    in hypoxic-ischemic brain injury,  
      588–589, 594, 841–842  
    in periventricular leukomalacia, 752  
  in hypoglycemia, 657–658

Glutamate dehydrogenase defects, in persistent hyperinsulinemic hypoglycemia of infancy, 249–250

Glutamine  
  for infections, 302  
  in nutrition, 52–56, 71–73

Glutathione peroxidase deficiency, in  
  hypoxic-ischemic brain injury, 590

Glycocalyx, intestinal, in host defense, 44–45

Glycogen storage diseases, hypoglycemia in, 251

Glycopyrrolate, for premedication, for endotracheal intubation, 543

Goblet cells, in host defense, 46

Gram-negative organisms, in meningitis, 798–799

Growth  
 brain, neuroimaging studies of  
     in impairment, 835–837  
     normal, 825–830  
 catch up, in preterm infants, 328–329  
 charts for, in nutritional assessment, of  
     preterm infants, 318–321  
 corticosteroids effects on, 303–305  
 in congenital heart defects, 340  
 intrauterine  
     adult glucose abnormalities and,  
         204–205  
     charts for, 318–321  
     normal mechanisms of, 205–207  
     nutritional requirements for,  
         228–230  
     rate of, 318  
     retardation of, 213–215, 329  
         in diabetes mellitus, 204–205  
         nutritional interventions  
             for, 339  
         postnatal growth and,  
             338–339  
         stroke in, 702–703  
 long-chain polyunsaturated fatty acids  
 effects on, 274–275

Growth factors, gastrointestinal trophic effects of, 79–82

Growth hormone  
 as pain marker, 422  
 deficiency of, hypoglycemia in, 250–251  
 gastrointestinal trophic effects of, 83

Gut-specific amino acids, in nutrition, 71–74

Gut trophic factor (glutamine), in nutrition, 52–56, 71–73

---

**H**

Halothane  
 for premedication, for endotracheal  
 intubation, 539, 544  
 surgical stress response suppression due  
 to, 417

Heart, congenital defects of  
 growth failure in, 340  
 stroke in, 707

Heart rate variability, 427–443  
 aperiodic, 430  
 at rest, 429  
 autonomic influences on, 430–431  
 decoding of, 428–431  
 frequency domain signals in, 430, 436

in endotracheal intubation, premedication  
 effects on, 538–542, 544–549

in pain assessment  
 baseline for, 437  
 composite multivariate scales  
 for, 438  
 methodological issues in, 436–437  
 opioid effects on, 437–438  
 patterns of, 432–436  
 physiologic interpretation of,  
     437–438  
 postoperative, 474  
 respiration effects on, 429–430, 435

short-term, 429, 437

time domain signals in, 429–430, 436

transfer function analysis of, 431

unrelated to pain, in intensive care  
 setting, 431–432

Hemochromatosis, cholestasis in, 173–174

Hemolysis, bilirubin neurotoxicity in, 771

Hemorrhage  
 intracranial, neuroimaging in, 846–847  
 intraventricular. *See also* Periventricular–  
 intraventricular hemorrhage.  
 neuroimaging in, 831–832

Hemorrhagic-ischemic brain injury, in preterm  
 infants, 743–761  
 in periventricular-intraventricular  
 hemorrhage, 743–750  
 in periventricular leukomalacia, 750–755

Hepatitis, neonatal, cholestasis in, 170

Hepatobiliary transporter defects, cholestasis  
 in, 171–172

Hepatocyte(s), disorders of, cholestasis in,  
 169–171

Hepatocyte growth factor, gastrointestinal  
 trophic effects of, 82

Hernia  
 diaphragmatic, prenatal versus postnatal,  
     3–4  
 inguinal, surgical repair of, 8

Herpes simplex virus, in central nervous  
 system infections, 806–809

Hippocampal injury, in very low birthweight  
 infants, 779–780

Hirschsprung's disease  
 pathophysiology of, 98  
 surgical treatment of, 10–11

Histamine<sub>2</sub> blockers  
 for gastroesophageal reflux, 152  
 pharmacology of, 124–126

HIV infection, of central nervous system, 811–812

Host defense, of gastrointestinal tract, 41–51  
breast milk components in, 42–43  
cytokines and chemokines in, 49–51  
enterocyte apical membrane in, 47  
epithelium in, 45–47  
gastric acid in, 43–44  
glycocalyx in, 44–45  
intracellular organelles and enzymes in, 47  
lactoferrin in, 48–49  
M cells in, 46  
microvilli in, 47  
motility in, 43  
mucus in, 44–45  
pancreatobiliary secretions in, 43–44  
subepithelial cells in, 48

hTAUT amino acid transporters, 209

Human immunodeficiency virus, in central nervous system infections, 811–812

Human milk. *See* Breast milk; Breastfeeding.

Human parvovirus B19, in central nervous system infections, 812–813

Hydrocephalus, in intraventricular hemorrhage, neuroimaging in, 831–832

Hydrogen peroxide, in hypoxic-ischemic brain injury, 589–590

Hydrops, fetal  
in congenital cystic adenomatoid malformation, 4  
in sacrococcygeal teratoma, 4–5  
stroke in, 701

Hyperalgesia, in vulnerable neonates, 375, 377

Hyperbilirubinemia. *See* Bilirubin, neurotoxicity of; Cholestasis.

Hypercapnia, permissive, in hypoxic-ischemic brain injury, 678–679

Hyperemia, postprandial, in intestinal circulation, 31

Hyperglycemia  
maternal or fetal, placental glucose transport in, 214–215  
neonatal, 246, 254–256

Hyperinsulinemia  
congenital, 14–15  
in infants of diabetic mothers, 247–248  
in persistent hyperinsulinemic hypoglycemia of infancy, 249–250

Hypertension  
early nutrition impact on, 204

maternal, fetal and newborn stroke in, 695–696

pregnancy-induced, periventricular-intraventricular hemorrhage and, 747

Hyperthermia, in hypoxic-ischemic brain injury, 642

Hypocarbia, periventricular leukomalacia and, 753–754

Hypoglycemia  
maternal or fetal, placental glucose transfer in, 207, 209–210  
neonatal, 247–254  
adverse effects of, 246  
alternative substrates to glucose and, 654–655  
asymptomatic, 651  
brain injury in  
biochemical alterations in, 656–659  
hypoxic-ischemic, 658, 660–661  
neuroimaging in, 663–665  
outcome of, 666–667  
pathology of, 665–666  
resistance to, 650  
seizures in, 661  
symptoms of, 662–663  
classic transitional, 662  
clinical aspects of, 661–662  
definition of, 247, 649–652  
early transitional, 661  
glucose transporters and, 655  
hyperinsulinemic, 14–15  
in amino acid metabolic defects, 254  
in Beckwith-Wiedemann syndrome, 248  
in carbohydrate metabolic disorders, 251–253  
in enzyme deficiencies, 251–254  
in erythroblastosis fetalis, 248  
in fatty acid metabolic defects, 254–255  
in fructose 1,6-diphosphatase deficiency, 251–252  
in fructose 1-phosphate aldolase deficiency, 252–253  
in galactose-1-phosphate uridyl transferase deficiency (galactosemia), 252  
in glycogen storage diseases, 251  
in hormone deficiencies, 250–251  
in infants of diabetic mothers, 247–248  
in persistent hyperinsulinemic hypoglycemia of infancy, 249–250  
in phosphoenolpyruvate carboxykinase deficiency, 252

in pyruvate carboxylase deficiency, 252  
incidence of, 650–652  
neuroimaging in, 663–665,  
844–846  
normal glucose metabolism and,  
652–654  
outcome of, 666–667  
pathophysiology of, 655–656  
preterm, 255  
risk factors for, 247–254  
secondary associated, 661–662  
severe recurrent, 662  
signs and symptoms of, 247  
small-for-gestational age, 248–249  
symptoms of, 662–663  
term, 247–251  
treatment of, 667–668

**Hypoketonemia**, in fatty acid metabolic defects, 253–254

**Hypotension**  
in hypoxic-ischemic brain injury, 838  
opioid-induced, 502  
periventricular-intraventricular hemorrhage in, 744

**Hypothermia**, for hypoxic-ischemic brain injury, 683–685, 843  
animal studies of, 625–632  
brain thermal regulation and, 638–640  
clinical implications of, 643–644  
clinical trials of, 643–644  
delayed, 630–632  
duration of, 628  
extent of, 628  
historical perspective of, 624–625  
immediate, 629–630  
methods for, 640–642  
mild to moderate, 628–632  
modest to moderate, 625–628  
pathogenic mechanisms and, 632–638  
time of initiation of, 627

**Hypothyroxinemia**, of prematurity, brain injury in, 781–782

**Hypotonia**, in stroke, 707–708

**Hypoxanthine**, accumulation of, in hypoxic-ischemic brain injury, 590

**Hypoxemia**, intestinal circulation response to, 30–31

**Hypoxia**, bilirubin neurotoxicity in, 770

**Hypoxic-ischemic brain injury**  
animal studies of, 586, 625–632  
hyperthermia effects on, 642  
hypoglycemia with, 658, 660–661  
neuroimaging in, 837–844  
pathogenesis of, 585–602, 632–638,  
837–841  
animal models of, 586  
apoptosis in, 594–595  
biochemical cascades in, 588–593  
calcium accumulation in, 589  
clinical implications of, 594–596  
cytokines in, 591–592, 594  
energy failure in, 587, 632–634  
excitotoxicity in, 588–589,  
635–636  
free radicals in, 589–590, 637–638  
hypoxia in, 586–587  
infections in, 587  
initiating mechanisms in, 586–587  
ischemia in, 587  
lipid mediators in, 592–593  
nitric oxide in, 590–591  
oligodendrocyte vulnerability in,  
593–594  
temperature effects on, 623–648. *See also Hypothermia*, for hypoxic-ischemic brain injury.  
animal studies of, 625–632  
clinical implications of, 642–644  
historical perspective of, 624–625  
in fever, 642  
mechanisms of, 632–638  
regulation of, 638–640  
treatment of, 673–690, 843  
based on pathogenic mechanisms,  
595–596  
fluid therapy in, 676–678  
hypothermia in. *See Hypothermia*,  
for hypoxic-ischemic  
brain injury.  
in delivery room, 673–676  
in meconium staining, 675  
neuroprotective, 679–685  
oxygen therapy for, 673–674  
pharmacologic, 675–676,  
679–683  
post resuscitation, 677–685  
temperature control in, 675  
ventilation in, 678–679

---

**I**

**Imaging**, of brain. *See Neuroimaging; specific modalities.*

**Immune globulin**, intravenous, for bacterial meningitis, 799

**Immunocytochemistry**, in animal studies of pain, 408–409

**Immunoglobulins**, intestinal, in host defense, 48

Immunonutrients, 51–59  
arginine, 56  
butyric acid, 58–59  
fatty acids, long-chain, 56–57  
glutamine, 52–56  
nucleotides, 57  
prebiotics, 57–58  
probiotics, 57–58

Imperforate anus, surgical treatment of, 13–14

Indomethacin  
for periventricular-intraventricular hemorrhage, 748  
maternal, neonatal effects of, 514

Infant-provider interaction, in very low birthweight infants, neurodevelopmental effects of, 784–785

Infants of diabetic mothers, hypoglycemia in, 247–248

Infarction, brain. *See* Stroke.

Infections  
intruterine, fetal and newborn stroke in, 698  
maternal  
antibiotics for, neurodevelopmental effects of, 726–731  
hypoxic-ischemic brain injury in, 587  
neonatal  
bilirubin neurotoxicity in, 767, 770–771  
central nervous system, 797–824  
bacterial, 797–799, 802  
fungal, 813–815  
mycobacterial, 815  
mycoplasma, 802–804  
protozoan, 815–818  
spirochetal, 800–801, 804–806  
viral, 806–813  
cholestatitis in, 169–170  
metabolic effects of, 296–302  
energy expenditure, 299–301  
functions of, 296  
implications of, for feeding, 301–302  
lipids, 300–301  
micronutrients, 300–302  
proteins, 297–299, 301

Inflammatory mediators, intestinal, in host defense, 49–51

Inflammatory pain, in vulnerable neonates, animal models of, 398, 400–401

Inguinal hernia, surgical repair of, 8

Insulin  
as pain marker, 421  
excess of. *See* Hyperinsulinemia.  
for hyperglycemia, 255  
in parenteral nutrition, for very low birthweight infants, 234–236  
resistance to, suboptimal intrauterine growth and, 204–205

Insulin-like growth factors  
gastrointestinal trophic effects of, 81–82  
in fetal growth, 214

Intelligence, in stroke, 714–715

Intensive care, heart rate variability in, 431–432

Interferon- $\gamma$ , gastrointestinal trophic effects of, 85

Interleukin(s)  
gastrointestinal trophic effects of, 85  
in host defense, 50–51  
in hypoxic-ischemic brain injury, 591–592  
in periventricular leukomalacia, 753

Intestinal circulation, 23–39  
adrenergic nerve stimulation effects on, 31  
arterial pressure effects on, 30  
basal vascular resistance in, 24–29  
in fetus, 24–25  
in first postnatal month, 25–26  
mechanisms of, 26–29  
diving reflex theory and, 32–33  
feeding effects on, 31  
hypoxemia effects on, 30–31  
necrotizing enterocolitis and, 32–36  
pathophysiology of, 32–36  
vascular responses in, 29–31

Intestine. *See also* Colon; Small intestine.  
atrophy of, in parenteral nutrition, 66–68  
circulation of. *See* Intestinal circulation.  
malrotation of, surgical treatment of, 9

Intracranial hemorrhage, neuroimaging in, 846–847

Intracranial pressure, in endotracheal intubation, premedication effects on, 540, 546

Intraepithelial lymphocytes, in host defense, 45–46

Intrauterine growth. *See* Growth, intrauterine.

Intraventricular hemorrhage. *See also* Periventricular-intraventricular hemorrhage.  
neuroimaging in, 831–832

Intubation, endotracheal, premedication for, 535–552

Iron status, of premature infants  
at birth, 284  
erythropoietin replacement effects on, 287–289  
evaluation of, 285–286  
iron supplementation effects on, 288–289  
long-term, 289–290  
metabolism of, 285  
requirements of, 284–285  
transfusion effects on, 286–287

**I**schemia, brain injury in. *See* Hemorrhagic-ischemic brain injury; Hypoxic-ischemic brain injury.

Islet cells, partial excision of, for hyperinsulinemia, 15

Isoflurane, for premedication, for endotracheal intubation, 544

## J

Jaundice. *See* Bilirubin, neurotoxicity of; Cholestasis.

Junctional complex, of intestinal epithelium, in host defense, 46

## K

Kangaroo care, for very low birthweight infants, 785

Kasai procedure, for biliary atresia, 165–167

Keratinocyte growth factor, gastrointestinal trophic effects of, 82

Kermicerus. *See* Bilirubin, neurotoxicity of.

Ketamine, for premedication, for endotracheal intubation, 540, 544

Ketone bodies, as cerebral metabolism fuel, 654, 660–661

Kidney  
dysfunction of, in hypoxic-ischemic brain injury, 677–678  
polycystic disease of, cholestasis in, 167

Kynurenic acid, for hypoxic-ischemic brain injury, 680–681

## L

Labor and delivery  
fetal and newborn stroke during, 704–705  
periventricular-intraventricular hemorrhage and, 747–748

Lactic acid  
as cerebral metabolism fuel, 654

formation of, opioid-induced, 840–841  
*Lactobacillus*, for short-bowel syndrome, 189

Lactoferrin, in host defense, 48–49

Language disorders, in stroke, 714–715

Lansoprazole, pharmacology of, 127

Laparoscopic surgery  
for gastroesophageal reflux, 7–8  
for Hirschsprung's disease, 11  
for imperforate anus, 14  
for inguinal hernia, 8  
for malrotation, 9  
for pyloric stenosis, 6–7

Laryngeal reflex, for reflux protection, 140

LAT amino acid transporters, 208

LCPUFAs. *See* Long-chain polyunsaturated fatty acids.

Legal issues, in pain management, 566–567

Leptomeningitis, syphilitic, 800–801, 804–805

Leukomalacia, periventricular. *See* Periventricular leukomalacia.

Leukotrienes, in hypoxic-ischemic brain injury, 592–593

Leukovorin, for toxoplasmosis, 816–817

Levobupivacaine, maternal, neonatal effects of, 514

Light conditions, in neonatal intensive care unit, neurodevelopmental effects of, 786–787

Linoleic acid, in nutrition  
adverse effects of, 274–275  
deficiency of, 266  
in breast milk, 266  
in formulas, 266  
metabolism of, 267  
sources of, 265–266  
structure of, 264

$\alpha$ -Linoleic acid, in nutrition  
in formulas, 266–267  
metabolism of, 267  
sources of, 265–266  
structure of, 264  
visual function and, 268

Lipase, in fat digestion, 263–264

Lipid(s). *See also* Fatty acids; Long-chain polyunsaturated fatty acids.  
absorption of, 263–264  
digestion of, 262–263  
for hyperglycemia, 255–256  
for preterm infants, 315–317

in parenteral nutrition, for very low birthweight infants, 236–237  
mediators of, in hypoxic-ischemic brain injury, 592–593  
metabolism of, 264  
corticosteroids effects on, 307  
in infections, 300–301  
placental transfer of, 208, 212–213  
requirements of, 261–262  
structured, for infections, 302  
structures of, 261–262

Liver  
biopsy of, in biliary atresia, 166  
cholestatic disease of. *See Cholestasis.*  
fibrosis of, cholestasis in, 167  
transplantation of, for gastrointestinal anomalies, 15–16

Liverpool Infant Distress Scale, 472, 474, 476

Local anesthesia, maternal, neonatal effects of, 514

Long-chain polyunsaturated fatty acids, in nutrition, 261–281  
adverse effects of, 274–275  
deficiency of, 266–267  
importance of, 264  
in breast milk, 266  
in formulas, 276  
intake of  
cognitive-behavioral development and, 270–273  
visual function and, 268–270  
medium-chain fat absorption and, 264  
metabolism of, 264–265, 267–268  
sources of, 265–266, 273–274  
structures of, 266–267  
supplementation with, 273–274, 276

Loperamide, for short-bowel syndrome, 186

Low birthweight infants. *See also* Extremely low birthweight infants.  
definition of, 329  
long-term growth of, 332

Lung, congenital cystic adenomatoid malformation of, fetal surgery for, 4

Lyme disease, of central nervous system, 805–806

Lymphocytes, intraepithelial, in host defense, 45–46

Lymphocytic choriomeningitis virus, in central nervous system infections, 813

**M**

M cells, intestinal, in host defense, 46

Macrosomia, glucose transfer in, 214

Magnesium sulfate  
for hypoxic-ischemic brain injury, 682  
maternal, neurodevelopmental effects of, 731–733

Magnetic resonance angiography, in stroke, 710

Magnetic resonance imaging  
in brain injury  
advantages of, 825–826  
diffusion-weighted, 827–828, 836–837  
hypoglycemic, 844–846  
in growth and development impairment, 835–837  
in intracranial hemorrhage, 846–847  
in intraventricular hemorrhage, 831–832  
in periventricular leukomalacia, 832–835  
three-dimensional, 827  
versus normal development, 825–830  
in stroke, 708, 710, 844

Magnetic resonance spectroscopy, in brain injury, 829–830, 840–843

Malabsorption, in short-bowel syndrome, 182

Malaria, congenital, 818

Malnutrition, maternal, offspring nutritional abnormalities related to, 203–205, 213–214

Malrotation, intestinal, surgical treatment of, 9

Manometry, in gastroesophageal reflux, 138–140, 148–149

Maple syrup urine disease, hypoglycemia in, 253

Mash1 protein, of enteric nervous system development, 109

Massage therapy, for very low birthweight infants, 785

Mast cells, intestinal, in host defense, 48

Maternal influences, on neurodevelopment, 364, 384–388. *See also* Neurodevelopmental effects, of maternal therapies.

Measles, of central nervous system, 812

Mechanical ventilation  
pain assessment in, 479–480  
periventricular-intraventricular hemorrhage and, 748

Meconium staining, in asphyxia, treatment of, 675

Meningitis  
  bacterial, 797–799, 802  
  fungal, 813  
  stroke in, 705  
  syphilitic, 800–801, 804–805  
  tuberculous, 815

Mental retardation, postoperative pain assessment in, 480–485

Meperidine, pharmacokinetics of, 495

Mesenchymal cells, in enteric nervous system development, 108

Mesoderm, enteric nervous system derived from, 99

Metabolic acidosis, bilirubin neurotoxicity in, 766, 770

Methohexitol, for premedication, for endotracheal intubation, 548–549

N-Methyl-D-aspartate receptors  
  antagonists to, for hypoxic-ischemic brain injury, 680–681  
  in fetal brain development, pain effects on, 361

Methylxanthines  
  brain injury due to, 781  
  gastrointestinal effects of, 127

Metoclopramide  
  for gastroesophageal reflux, 151  
  pharmacology of, 117–119

Microvilli, intestinal, in host defense, 47

Midazolam  
  for premedication, for endotracheal intubation, 536, 545, 549  
  surgical stress response suppression due to, 418

Milk, human. *See* Breast milk; Breastfeeding.

Minerals  
  deficiencies of, in infections, 300–302  
  in formulas, for preterm infants, 337

Minimal enteral feeding, intestinal mucosal effects of, 67–68

MK-801, for hypoxic-ischemic brain injury, 680–681

Modified Behavioral Pain Scale, 475

Modified Infant Pain Scale, 473–474, 476–477

Morphine  
  adverse effects of, 501–502  
  clinical efficacy of, 499–500  
  dosage for, 504–505, 515  
  effects of, 514–515

for premedication, for endotracheal intubation, 536

maternal, neonatal effects of, 513–514, 516–517

metabolism of, polymorphisms in, 522–524

pharmacodynamics of, 496–497

pharmacokinetics of, 494–495, 514–515, 518–519

surgical stress response suppression due to, 417

withdrawal from, 503

Motility, gastrointestinal  
  enteric nervous system in. *See* Enteric nervous system.  
  in host defense, 43  
  measurement of, in gastroesophageal reflux, 149

Mucus, intestinal, in host defense, 44–45

Multiple gestation, stroke in, 701–702

Muscle rigidity, opioid-induced, 502

Music therapy, for very low birthweight infants, 786

Mutation studies, of enteric nervous system development, 103

*Mycoplasma hominis*, in central nervous system infections, 802–804

Mydrinates, gastrointestinal effects of, 127–128

Myelination, in brain growth and development, 826–828, 835–837

Myelomeningocele, fetal surgery for, 5

Myo-inositol, increase of, in hypoxic-ischemic brain injury, 842–843

Myogenic response, in intestinal circulation regulation, 28

---

**N**

Naloxone, for opioid reversal, 500, 502

Narcotics. *See* Opioids.

Nex transcription factor, of enteric nervous system development, 109

Necrotizing enterocolitis  
  intestinal circulation and, 32–36  
  prevention of, nutritional practices for, 238–239  
  surgery for, 12–13  
    pain severity in, 470–471  
    short-bowel syndrome after, 182

Needlestick pain, in vulnerable neonates, animal models of, 398

Neonatal Facial Coding System, for pain assessment, 471, 478

Neonatal Infant Pain Scale, 475

Neonates, vulnerable, pain in. *See* Pain, in vulnerable neonates.

Nerve ligation, in vulnerable neonates, animal models of, 399

Nervous system, enteric. *See* Enteric nervous system.

Neural crest, enteric nervous system derived from, 99–104

Neuroborreliosis, 805–806

Neurodevelopmental effects  
of dietary fatty acids and, 270–273  
of hypoglycemia, 666–667  
of maternal therapies, 723–741  
antibiotics, 726–731  
corticosteroids, 733–735  
phenobarbital, 736  
surrogate markers of, 725–726  
thyrotropin-releasing hormone, 735–736  
tocolytics, 731–733  
vitamin K, 736

of pain  
long-term outcome of, 373–394  
altered pain response, 380–382  
cerebral blood flow autoregulation immaturity, 380  
environmental factors in, 382–388  
hyperalgesia, 375, 377  
intrinsic factors in, 382–388  
low pain threshold, 375  
model of, 376  
neurologic deficits, 378–380  
schematic summary of, 374  
sensitization, 375, 377

neuronal mechanisms in, 357–372  
behavioral, 357–359  
imaging studies of, 359–360  
immaturity, 361–362  
in fetus, 366–367  
intensive care unit environment, 363–364  
maternal influences on, 364, 384–388  
repetitive, 364–366

of periventricular-intraventricular hemorrhage, 748–749

of periventricular leukomalacia, 755  
of stroke, 713–715

Neuroimaging  
in brain injury, 825–852  
hypoglycemic, 663–665, 844–846  
hypoxic-ischemic, 837–844  
in focal ischemic infarction, 844  
in full-term infants, 837–847  
in growth and development impairment, 835–837  
in intracranial hemorrhage, 846–847  
in intraventricular hemorrhage, 831–832  
in periventricular leukomalacia, 832–835  
in preterm infants, 831–837  
in stroke, 844  
versus normal development, 825–830

in pain-related neurodevelopmental deficits, 359–360

Neurologic disorders  
in cytomegalovirus infections, 808–809  
in herpes simplex virus encephalitis, 808–809  
in HIV infection, 811  
in stroke, 707–708, 713–715  
in toxoplasmosis, 815–817  
postoperative pain assessment in, 480–485

Neuron(s), subplate, organizational disturbance in, in very low birthweight infants, 778–779

Neurotensin, gastrointestinal trophic effects of, 79

Neurotransmitters, impairment of, in hypoxic-ischemic brain injury, 594, 841–842

Nicardipine, for hypoxic-ischemic brain injury, 681

Nitric oxide  
deficiency of, in necrotizing enterocolitis, 34–35  
for hypoxic-ischemic brain injury, 678  
in hypoxic-ischemic brain injury, 590–591  
in intestinal circulation regulation, 27

Nitrogen balance, in infections, 297–299

Nitrous oxide  
for premedication, for endotracheal intubation, 544  
surgical stress response suppression due to, 418

Noise control, for very low birthweight infants, 785–786

Non-Communicating Children's Pain Checklist, 481–484

Norepinephrine as pain marker, 419–420  
in fetus, 512  
constrictor activity of, in necrotizing enterocolitis, 34

Nucleotides, in nutrition, 57, 74–75

Nursing Assessment of Pain Intensity, 472, 475–476

Nutrition, 65–77  
aggressive  
description of, 227  
enteral, 237–241  
parenteral, 230–237  
arginine in, 56, 73  
assessment of, in preterm infants, 318–324  
breast milk in  
components of, in gastrointestinal host defense, 42–43  
for gastroesophageal reflux, 150  
versus formula, 68–70  
butyric acid in, 58–59, 75–76  
deficiencies in, in short-bowel syndrome, 187  
enteral, for short-bowel syndrome, 183–184  
fatty acids in  
long-chain, 56–57, 76–77  
short-chain, 75–76  
for cholestasis, 174–175  
for gastroesophageal reflux, 150–151  
for preterm infants, 313–326  
for very low birthweight infant, 225–244, 783  
glucose extremes and, 245–260  
glutamine in, 52–56, 71–73  
gut-amino acids in, 71–74  
immunonutrients in, 51–59  
importance of, 203–223  
for cardiovascular system, 203–204  
for growth, 204–205  
placental transfer and, 205–208  
amino acids, 208–213  
glucose, 207–210  
in pathologic states, 213–215  
lipids, 208, 212–213  
postnatal, 215–216  
thrift hypothesis and, 203–205, 328–329  
in anemia of prematurity, 283–294  
long-chain polyunsaturated fatty acids in, 261–281  
macronutrient composition in, 70–71  
metabolism in, 295–312  
infection effects on, 296–302

postnatal steroids effects on, 302–307  
mode of administration of, 66–68  
nucleotides in, 57, 74–75  
parenteral. *See Parenteral nutrition.*  
postdischarge, 327–344  
prebiotics in, 57–58  
probiotics in, 57–58

## O

Obesity, breastfeeding protection against, 215–216

Objective Pain Scale, 473–474, 476

Oligodendrocytes, vulnerability of in fetus, 362  
in hypoxic-ischemic brain injury, 593–594  
in periventricular leukomalacia, 752

Omega-fatty acids. *See Long-chain polyunsaturated fatty acids.*

Omeprazole, pharmacology of, 126–127

Opioids  
changing attitudes toward, 557  
for fetal surgery, 367  
heart rate variability and, 437–438  
pharmacokinetics of, 516–517  
pharmacology of, 493–509, 516–517  
administration, 504–505  
adverse effects, 500–504  
clinical efficacy, 498–500  
dosage, 504–505  
pharmacodynamics, 496–498  
pharmacokinetics, 494–496  
tolerance, 503, 518  
withdrawal, 503

receptors for, polymorphisms in, 525

surgical stress response suppression due to, 417–418

Organelles, in intestinal cells, in host defense, 47

Ornithine, in nutrition, 73

Osteopenia, laboratory studies for, in nutritional assessment of preterm infants, 323

Oxidative phosphorylation, impairment of, in hypoxic-ischemic brain injury, 841

Oxygen consumption, measurement of, in infections, 299

Oxygen free radicals  
in hypoxic-ischemic brain injury, 589–590, 594, 637–638  
in periventricular leukomalacia, 752

## Oxygen tension

in pain assessment, postoperative, 474  
transcutaneous, in endotracheal intubation, premedication effects on, 540–541, 546

## Oxygen therapy, for hypoxic-ischemic brain injury, 673–674

**P**

## Paediatric Pain Profile, 482–484

## Pain

in fetus. *See Fetus, pain in.*  
in vulnerable neonates  
assessment of  
biologic markers for, 415–425  
body language in, 450  
challenges of, 445–457  
clinical significance of, 459–468  
crying in, 449  
facial activity in, 449–450  
heart rate variability in, 427–443  
physiologic activity in, 450–451  
postoperative, 469–491  
clinical significance of, 459–468  
ethical issues in, 566–567  
experience of, 447–448  
expression of, 448–449, 451–453  
failure to express, 449–450,  
453–454  
in endotracheal intubation, 535–552  
in sleep, heart rate in, 433  
learning about, 565  
legal issues in, 566–567  
long-term consequences of, 373–394  
animal models of, 395–414  
low threshold for, 375  
management of. *See also*  
Analgesia; Anesthesia;  
Opioids: specific agents.  
advocacy for, 559–560  
beliefs about, 454  
changing practice of, 556–558  
clinical significance of, 459–468  
effects of, 511–534  
opioids in, 493–509,  
516–517  
parents involvement in, 559–560  
public pressure effects on, 562  
resistance to changes in, 563–565  
safety of, 558  
standards of care for, 565–567  
memory of, 448  
neurodevelopment and, animal models of, 357–372  
perception of  
Anand research on, 561–562  
beliefs about, 447–448,  
453–454, 556–558  
in circumcision, heart rate in, 433–434  
physiologic activity in, 450–451  
postoperative, assessment of, 469–491  
prevalence of, 374, 554–555  
procedures causing, 558  
reduction of, 554–555  
repetitive  
animal studies of, 395–414  
long-term consequences of, 409–411  
outcome measures for, 399–401  
paradigms used in, 397–399  
rat pup choice for, 397  
summary of, 402–409  
value of, 396–397  
neurodevelopmental effects of, 364–366  
response to, alterations of, 380–382  
sensitization to, 375, 377  
social context of, 553–570  
twins, 513  
versus other adverse states, 451

Pain Assessment Tool, 472, 474–476, 480

Pain Evaluation Scale for Cerebral Palsy, 481–484

Pain Observation Scale for Young Children, 473–476

Pancreas, secretions of, in host defense, 43–44

Pancreatectomy, subtotal or partial  
for hyperinsulinemia, 15  
for persistent hyperinsulinemic hypoglycemia of infancy, 250

Pancuronium  
for muscle rigidity, opioid-induced, 502  
for premedication, for endotracheal intubation, 539–541, 544

Parenteral nutrition  
cholestasis associated with, 174, 187  
for hyperglycemia, 255–256

for infections, 301  
for short-bowel syndrome, 184–187, 191  
for very low birthweight infants,  
    230–237  
hyperglycemia in, 246  
intestinal mucosal effects of, 66–68

Parents  
    in neonatal pain management  
        decisions, 564  
    pain assessment measure for, 485–487

Parvovirus B19, in central nervous system infections, 812–813

Pax2 transcription factor, of enteric nervous system development, 109

Penicillin(s), for bacterial meningitis, 797

Penicillin G, for syphilis, 800–801

Pentazocine, maternal, neonatal effects of,  
    513–514, 516

Peptide YY, trophic effects of, 78–79

Perfusion pressure, reduction of, intestinal circulation response to, 30

Peritoneal drainage, for necrotizing enterocolitis, 12–13

Periventricular-intraventricular hemorrhage,  
    743–750  
        clinical features of, 746–747  
        incidence of, 743–744  
        neuropathology of, 744  
        outcome of, 749–750  
        pathogenesis of, 744–746  
        prevention of, 747–749  
        white matter injury in, 746

Periventricular leukomalacia, 750–755  
    clinical features of, 753–754  
    description of, 750  
    neuroimaging in, 832–835  
    neuropathology of, 750–751  
    outcome of, 755  
    pathogenesis of, 751–753  
    prevention of, 754–755

Peroxidation, lipid, in hypoxic-ischemic brain injury, 592–593

Persistent hyperinsulinemic hypoglycemia of infancy, 249–250

Pethidine  
    for premedication, for endotracheal intubation, 542, 549  
    maternal, neonatal effects of, 513–514

Peyer's patches, in host defense, 48

pH measurement, in gastroesophageal reflux,  
    147–148

Pharmacodynamics and pharmacokinetics. *See specific drugs.*

Pharmacology, of gastrointestinal tract,  
    115–133  
        adverse drug effects, 127–128  
        developmental influences on, 116–117  
        prokinetic agents, 117–126  
        proton pump inhibitors, 126–127

Phenobarbital  
    for hypoxic-ischemic brain injury,  
        681–682  
    for periventricular-intraventricular hemorrhage, 747  
    maternal, neurodevelopmental effects of, 736

Phosphate, in formulas, for preterm infants, 337

Phosphoenolpyruvate carboxykinase deficiency, hypoglycemia in, 252

Phototherapy, for bilirubin neurotoxicity, 769

Phox2b transcription factor, of enteric nervous system development, 109

Placenta  
    bypass with, during ex utero intrapartum therapy, 4  
    disorders of, fetal and newborn stroke in,  
        697–698  
    nutrient transfer in, 205–208  
        amino acids, 208–213  
        energy costs of, 206–207  
        glucose, 207–210  
        in pathologic states, 213–215  
        lipids, 208, 212–213

Platelet-activating factor, in hypoxic-ischemic brain injury, 592–593

Pleconaril, in enteroviral infections, 810

Polycythemia, with hyperviscosity, stroke in,  
    705–706

Portoenterostomy (Kasai procedure), in biliary atresia, 165–167

Postoperative pain, 469–491  
    assessment of  
        in cognitive impairment, 480–485  
        in critical illness, 479–480  
        in neurologic impairment,  
            480–485  
        instruments for, 471–478  
        parent involvement in, 485–487  
        timing of, 478  
    concurrent medical conditions and,  
        470–471  
    versus surgery type, 470–471

Postoperative Pain Measure for Parents, 485–487

Postoperative Pain Scale, 472, 474, 476

Postprandial hyperemia, in intestinal circulation, 31

Posture, in gastroesophageal reflux management, 150

Potassium channel defects, in persistent hyperinsulinemic hypoglycemia of infancy, 249–250

Pre-eclampsia, fetal and newborn stroke in, 695–696

Pre-Verbal, Early Verbal Pediatric Pain Scale, 473, 475–476

Prebiotics, as immunonutrients, 57–58

Prednisone, for toxoplasmosis, 816–817

Pregnancy, analgesia in, neonatal effects of, 513–514, 516

Premature Infant Pain Profile, 461–462, 472, 474–475, 480

Premature rupture of membranes, antibiotics for, neurodevelopmental effects of, 730–731

Premedication, for endotracheal intubation, 535–552

Prenatal diagnosis, of gastrointestinal anomalies, 2–5

Pressure-flow autoregulation, in intestinal circulation, 30

Preterm infants

- anemia of. *See Anemia of prematurity.*
- bilirubin neurotoxicity in, 771–772
- brain injury in, neuroimaging in, 831–837
- cerebral palsy in, chorioamnionitis related to, 606–608
- classification of, 329
- glucose homeostasis in, 246
- growth of, 329–333
  - catch up, 328–329
  - long-term, 332–333
- hemorrhagic-ischemic brain injury in, 743–761
- hypoglycemia in, 254
- infections in, nitrogen balance in, 299
- neurodevelopment of, maternal therapy effects on, 723–741
- nutrition for, 313–326
  - assessment of, 318–324
  - anthropometric measurements in, 318

growth charts in, 318–321

laboratory indices in, 322–324

weight gain rate in, 321–322

feeding tolerance and, 316, 318

goals of, 313

interventions for, 314–317

postdischarge, 327–344

- breastfeeding, 338
- fetal programming and, 328–329

formulas, 334–336

growth rate and, 329–333

in bronchopulmonary dysplasia, 339–340

in cardiac disease, 340

minerals, 337

protein, 337

pain in. *See Pain, in vulnerable neonates.*

very low birthweight. *See Extremely low birthweight infants; Very low birth-weight infants.*

#### Probiotics

as immunonutrients, 57–58

for short-bowel syndrome, 189

Procaine penicillin G, for syphilis, 800

Progressive familial intrahepatic cholestasis, 171–172

#### Prokinetic agents

for gastroesophageal reflux, 151–152

pharmacology of, 117–126

Prolactin, as pain marker, 422

Proline, in nutrition, 73

Prostaglandins, in hypoxic-ischemic brain injury, 592–593

#### Protein. *See also Amino acids.*

in formulas, for preterm infants, 337

metabolism of, corticosteroids effects on, 305–306

requirements of

- for fetal growth, 228–230
- for very low birthweight infants, 240

in infections, 297–299, 301

serum, monitoring of, in nutritional assessment of preterm infants, 323

supplements for, for preterm infants, 314–315, 317

synthesis of, defects of, in hypoxic-ischemic brain injury, 637

Protein C, activated, resistance to, fetal and newborn stroke in, 697

#### Proton pump inhibitors

for gastroesophageal reflux, 152

pharmacology of, 126–127

*Pseudomonas aeruginosa*, in meningitis, 799

Pyloric stenosis, surgical treatment of, 6–7

Pyrimethamine, for toxoplasmosis, 816–817

Pyruvate carboxylase deficiency,  
hypoglycemia in, 252

## R

Ranitidine, pharmacology of, 124–126

Rationalization, in neonatal care workers, pain  
management decisions and, 563–565

Reactive oxygen species, in hypoxic-ischemic  
brain injury, 589–590, 594

### Reflex

diving, necrotizing enterocolitis  
pathophysiology and, 32–33

laryngeal, for reflux protection, 140

Reflux, gastroesophageal. *See Gastroesophageal reflux.*

Regurgitation, in gastroesophageal reflux, 144

Renin, as pain marker, 421

### Respiration

heart rate variability with, 429–430, 435  
in endotracheal intubation, premedication  
effects on, 542

Respiratory acidosis, bilirubin neurotoxicity in,  
766, 770

Respiratory depression, opioid-induced, 501

Respiratory disorders, in very low birthweight  
infants, brain injury in, 781

Respiratory sinus arrhythmia, 429

### Resuscitation

in hypoxic-ischemic brain injury,  
626–627, 629–632, 673–676  
stroke in, 706

*Ret* gene, in enteric nervous system  
development, 107–108

Riley Infant Pain Scale, 472, 476

Rubella, of central nervous system, 812

Rumination, in gastroesophageal reflux, 144

## S

Sacrococcygeal teratoma, fetal surgery for, 4–5

Scale for Use in Newborns, for pain  
assessment, clinical utility of, 462

Scintigraphy, in gastroesophageal reflux, 149

Sclerosing cholangitis, 167

Sedation, opioid-induced, 501–502

### Seizures

in hypoglycemia, 661  
in hypoxic-ischemic brain injury,  
treatment of, 679–680  
in stroke, 707–708, 714  
opioid-induced, 502

Sensitivity tests, in animal models of pain,  
399–400

Sensitization, to pain, in vulnerable neonates,  
375, 377

### Sepsis

bilirubin neurotoxicity in, 767  
catheter-related, in short-bowel  
syndrome, 188  
cholestasis in, 169–170  
metabolic effects of, nutritional aspects  
of, 296–302

Short-bowel syndrome, 181–194

complications of, 186–187  
definition of, 181  
etiology of, 182  
intestinal adaptation to, 182–183  
management of, 183–186  
enteral feedings in, 183–184  
medications in, 188–189  
parenteral nutrition in,  
184–187, 191  
postoperative, 183  
surgical, 189  
transplantation in, 189–191  
pathophysiology of, 182

Signaling pathways, in enteric nervous system  
development, 105–108

Silo, spring-loaded, for gastroschisis, 12

### Sleep

pain perception in, heart rate in, 433  
patterns of, in pain assessment, 471–473

Small-for-gestational-age infants  
growth of, 329, 338–339  
hypoglycemia in, 248–249  
nutrition for, 339

### Small intestine

adaptation of, in short-bowel syndrome,  
182–183  
bacterial overgrowth in, in short-bowel  
syndrome, 187–188  
herniation of, through abdominal wall  
(gastroschisis), 11–12  
malrotation of, surgical treatment of, 9  
necrosis of, surgical treatment of, 12–13  
perforation of, spontaneous, 13

resection of, short-bowel syndrome after.  
See Short-bowel syndrome.

transplantation of  
for gastrointestinal anomalies, 16  
for short-bowel syndrome,  
189–191

Social behavior, in pain assessment, 482

Social conditions, postdischarge, for very low birthweight infants, 787

Social context, of neonatal pain, 553–570  
changing practices of, 556–558  
communication aspect of, 553, 555–556  
learning about pain, 565  
pressure for change, 559–561  
prevalence of pain, 554–555  
research on, 567–568  
resistance to change, 563–565  
standards of care and, 565–567

Sociocommunication model of pain, 446–454,  
555–556

Sodium, in amino acid transport, 210–211

Sodium bicarbonate, as pain marker, 676

Somatostatin, for short-bowel syndrome, 186

Somatostatin analogues, for persistent hyperinsulinemic hypoglycemia of infancy, 250

Sox10 transcription factor, of enteric nervous system development, 109

Spiramycin, for toxoplasmosis, 817

Spring-loaded silo, for gastroschisis, 12

Standards of care, for pain management, 565–567

*Staphylococcus aureus*, in meningitis, 799

Steroids. See Corticosteroids.

Streptococci, group G, in meningitis, 797–798

Stress, response to, 416–419  
biological markers of, 418–422  
in anesthesia, 419–420, 561–562  
in animal models of pain, 401, 408  
in fetus, 383, 512–513  
in surgery, 419–420  
with inadequate anesthesia, 561–562

Stroke, 691–722  
causes of  
fetal factors, 700–704  
maternal factors, 695–699  
neonatal conditions, 705–707  
peripartum, 704–705  
placental disorders, 699–700

clinical features of, 707–708  
epidemiology of, 691–693  
evaluation of, 708–713  
hemispheric involvement in, 710–711  
history in, 692–693  
imaging in, 708–711, 844  
in intraventricular hemorrhage,  
neuroimaging in, 831–832  
neurodevelopmental outcome of,  
713–715  
neurophysiologic studies in, 708–709  
risk factors for, 694  
timing of, from fetal to neonatal life,  
693, 695  
treatment of, 715–716

Subepithelial cells, intestinal, in host defense, 48

Succinylcholine, for premedication, for endotracheal intubation, 536, 541–542, 544, 547, 549

Sudden infant death syndrome, gastroesophageal reflux and, 145

Sufentanil, surgical stress response suppression due to, 417

Sulfadiazine, for toxoplasmosis, 816–817

Sulfonylurea receptor defects, in persistent hyperinsulinemic hypoglycemia of infancy, 249–250

Surgery  
metabolic response to, 296–297  
postoperative pain in. See Postoperative pain.  
stress response to  
anesthesia effects on, 417–418  
markers of, 418–422  
without anesthesia, 559–560

Suxamethonium, for premedication, for endotracheal intubation, 543, 549

Syncytiotrophoblasts, nutrient transfer in, 205–206, 211–212

Syphilis, of central nervous system, 800–801, 804–805

Systemic lupus erythematosus, maternal, fetal and newborn stroke in, 695

## T

T lymphocytes, intraepithelial, in host defense, 45–46

Temperament, neurodevelopmental outcome and, 382–383

Temperature, in hypoxic-ischemic brain injury.  
See Hypoxic-ischemic brain injury.  
temperature effects on: Hypothermia,  
for hypoxic-ischemic brain injury.

Teratoma, sacrococcygeal, fetal surgery for,  
4–5

Thiopental  
for hypoxic-ischemic brain injury,  
681–682  
for premedication, for endotracheal  
intubation, 538, 544, 546–547

Thiopentone, for premedication, for  
endotracheal intubation, 539, 544

Threonine, in nutrition, 73–74

Thrifty hypothesis, in intrauterine growth,  
203–205, 328–329

Thrombophilia, maternal, fetal and newborn  
stroke in, 696–698

Thrombosis, of placenta, fetal and newborn  
stroke in, 697–698

Thromboxanes, in hypoxic-ischemic brain  
injury, 592–593

Thyroid hormone  
deficiency of, in very low birthweight  
infants, brain injury in, 781–782  
gastrointestinal trophic effects of, 83–84

Thyrotropin-releasing hormone, maternal,  
neurodevelopmental effects of, 735–736

Tight junctions, of intestinal epithelium, in host  
defense, 46

Tissue injury, in vulnerable neonates, animal  
models of, 398

Tissue recombination studies, of enteric  
nervous system development, 102–103

Tocolytics, neurodevelopmental effects of,  
731–733

Toddler Pre-schooler Postoperative Pain Scale,  
473, 476

Tolerance, of opioids, 503–504, 518

Toxoplasmosis, of central nervous system,  
815–817

Trachea  
intubation of, premedication for, 535–552  
occlusion of, in fetus, for diaphragmatic  
hernia, 3–4

Tracheoesophageal atresia, surgical treatment  
of, 8–9

Transcriptional regulation, of enteric nervous  
system development, 108–109

Transforming growth factor- $\alpha$   
gastrointestinal trophic effects of,  
80–81  
in host defense, 51

Transforming growth factor- $\beta$ , gastrointestinal  
trophic effects of, 84–85

Transgenic models, for enteric nervous system,  
104–105

Transplantation  
liver, for gastrointestinal anomalies,  
15–16  
small intestinal  
for gastrointestinal anomalies, 16  
for short-bowel syndrome,  
189–191

*Treponema pallidum* infections, of central  
nervous system, 800–801, 804–805

Triangular cord sign, in biliary atresia, 166

Trk receptors, in enteric nervous system  
development, 108

Trophic feeding, intestinal mucosal effects of,  
67–68

Tuberculosis, of central nervous system, 815

Tumor necrosis factor- $\alpha$   
in hypoxic-ischemic brain injury,  
591–592  
in periventricular leukomalacia, 753  
inhibitors of, for infections, 302  
intestinal, in host defense, 50–51

Twin-twin transfusion  
stroke in, 701–702  
treatment of, 5

Twins, pain perception in, 513

---

**U**

Ultrasoundography  
in biliary atresia, 166  
in gastrointestinal anomalies, 2–5  
in intraventricular hemorrhage, 831–832  
in periventricular leukomalacia, 832  
in stroke, 710

University of Wisconsin Children's Hospital  
Pain Scale, 484

*Ureaplasma urealyticum*, in central nervous  
system infections, 802–804

Urinary retention, opioid-induced, 502

---

**V**

Vagal Tone Index, 430, 433

Varicella-zoster virus, in central nervous system infections, 812

Vascular access, for gastrointestinal disorders, 10

Vascular endothelial growth factor, gastrointestinal trophic effects of, 82

Vascular resistance, basal, of intestinal circulation, 24–29  
in fetus, 24–25  
in first postnatal month, 25–26  
mechanisms of, 26–29

Venous thrombosis, cerebral, stroke in, 707

Ventilation, in hypoxic-ischemic brain injury, 678–679

Ventriculoperitoneal shunt, in fetus, 5

Very low birthweight infants  
brain injury in, 777–795  
pathogenesis of, 777–780  
postdischarge social and environmental influences on, 787  
predisposition to  
clinical factors in, 780–784  
environmental factors in, 784–787  
definition of, 329  
long-term growth of, 332  
nutrition for, 225–244  
aggressive, 227, 230–241  
enteral, 237–241  
general considerations in, 226–227  
in early neonatal period, 238–240  
in growing period, 240–241  
inadequate, consequences of, 226–227  
parenteral, 230–237  
requirements for, 228–230

Vidarabine, for herpes simplex virus infections, 807

Viral infections  
cholestasis in, 170  
of central nervous system, 806–813

Visual Analogue Scale, for pain assessment, 463–464, 471, 478

Visual function, dietary fatty acids and, 268–270

Vitamin(s)  
deficiencies of  
in infections, 300–302  
in short-bowel syndrome, 187  
for cholestasis, 175  
in formulas, for preterm infants, 337

Vitamin K  
for periventricular-intraventricular hemorrhage, 747  
maternal, neurodevelopmental effects of, 736

Volvulus, surgical treatment of, 9

Vomiting, in gastroesophageal reflux, 144

von Gierke's disease, hypoglycemia in, 251

Vulnerable neonates, pain in. *See Pain, in vulnerable neonates.*

---

**W**

Weight  
birth  
adult and childhood nutritional abnormalities related to, 203–205, 213–214  
regaining of, in premature infants, 318  
very low. *See Extremely low birthweight infants; Very low birthweight infants.*  
fetal, versus nutritional requirements, 228–230  
gain of, in nutritional assessment, of preterm infants, 321–322

White matter, injury of  
in periventricular hemorrhage, 746  
in periventricular leukomalacia, 750–755

Withdrawal, from opioids, 503–504

---

**X**

Xanthine oxidase inhibitors, for hypoxic-ischemic brain injury, 682–683

---

**Z**

Zinc, in formulas, for preterm infants, 337

